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Complete inactivation of the PTEN tumor suppressor gene is extremely common in advanced cancer, including prostate
cancer (CaP). However, one PTEN allele is already lost in the vast majority of CaPs at presentation. To determine the
consequence of PTEN dose variations on cancer progression, we have generated by homologous recombination a
hypomorphic Pten mouse mutant series with decreasing Pten activity: Ptenhy/þ. Ptenþ/. Ptenhy/ (mutants in which
we have rescued the embryonic lethality due to complete Pten inactivation) . Pten prostate conditional knockout
(Ptenpc) mutants. In addition, we have generated and comparatively analyzed two distinct Ptenpc mutants in which Pten
is inactivated focally or throughout the entire prostatic epithelium. We find that the extent of Pten inactivation dictate
in an exquisite dose-dependent fashion CaP progression, its incidence, latency, and biology. The dose of Pten affects
key downstream targets such as Akt, p27Kip1, mTOR, and FOXO3. Our results provide conclusive genetic support for the
notion that PTEN is haploinsufficient in tumor suppression and that its dose is a key determinant in cancer progression.
Introduction
The PTEN (phosphatase and tensin homolog deleted on
chromosome 10) tumor suppressor gene is located on
chromosome 10q23, a genomic region frequently lost in
human cancers. Somatic deletions or mutations of this gene
have been identified in a large fraction of tumors, frequently
in prostate cancer (CaP), placing PTEN among the most
commonly mutated tumor suppressor genes in human cancer
(Cantley and Neel 1999; Di Cristofano and Pandolfi 2000).
As dictated by Knudson’s ‘‘two-hit’’ hypothesis (Knudson
1971), however, the analysis of cancer samples for mutations
in PTEN has been performed searching for biallelic inactiva-
tion of the gene, which pointed at complete PTEN inactiva-
tion as a late event in cancer progression. The consequence of
loss or mutation in one PTEN allele in carcinomas in situ or
in primary cancers may have been underestimated. It could
be postulated that if PTEN were to be haploinsufficient for
some of its tumor-suppressive functions, loss of one PTEN
allele or reduction in its expression may be playing a key role
in tumor initiation, while further reduction of its function/
expression may favor invasion and possibly tumor metastasis
in advanced cancers.
In agreement with this hypothesis, it has been reported that
primary tumors often show loss or alteration of at least one
PTEN allele (e.g., 70%–80% of primary CaPs; Gray et al. 1998;
Whang et al. 1998), while homozygous inactivation of PTEN is
generally associated with advanced cancer and metastasis
(Cantley and Neel 1999; Di Cristofano and Pandolfi 2000),
supporting a possible key role for progressive PTEN func-
tional loss in tumor progression.
The elucidation of the molecular basis for tumor initiation
and progression in most epithelial neoplasms has been
hindered by the lack of suitable laboratory and preclinical
models that accurately reflect the genetic and histopatho-
logical progression of these cancers. Furthermore, the
outcome of a progressive dose reduction in tumor suppressor
function has been rarely assessed in vivo in the mouse. Small
interfering RNA (siRNA) technology has more recently
allowed testing the consequence of knockdown of a tumor
suppressor such as p53 in specific cell types such as
hemopoietic stem cells, by generating epi-allelic series of
hypomorphs created by stable RNA interference (RNAi)
transduction (Hemann et al. 2003). In the case of Pten, this
analysis is further complicated since complete inactivation of
the gene results in early embryonic lethality and aberrant
developmental programs (Di Cristofano et al. 1998, 2001a;
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Suzuki et al. 1998; Podsypanina et al. 1999). Thus, a further
unrestricted reduction of the Pten dose could still result in
embryonic lethality. On the other hand, the consequence of
complete Pten inactivation, even when restricted to a specific
organ/tissue, could still affect the developmental program of
that organ, while complete somatic loss of Pten in an adult
organ would better approximate what is normally observed in
human cancer. We have addressed these issues for Pten, as we
describe in this article, through the generation of (i)
hypomorphic mouse mutants and (ii) conditional mutants
for complete prostate-specific Pten inactivation after puberty.
We previously reported that Pten heterozygous (Ptenþ/)
mutants are prone to develop neoplasms of various histo-
logical origins, including prostatic intraepithelial neoplasias
(PIN) after a long latency ( .14 mo) and at incomplete
penetrance (40%) (Di Cristofano et al. 2001a). Ptenþ/
mutants, however, never develop invasive CaPs. Invasive CaPs
were, by contrast, observed in compound Ptenþ//p27Kip1þ/ or
Ptenþ//p27Kip1/ mutants (Di Cristofano et al. 2001a). These
lesions appeared to originate in PIN lesions, which then
become invasive. However, no metastatic CaP was observed in
this model, also in view of early lethality due to the
occurrence of concomitant tumors of various histogenesis.
Analysis of tumors, PIN, and CaP in Ptenþ/ mice and Pten/
p27Kip1 compound mutants strongly suggested that Pten may
be haploinsufficient in prostate tumor suppression since Pten
protein expression was never lost in these lesions. If this was
indeed the case, a further reduction in the Pten dose with
respect to Ptenþ/ mutants should impact on tumorigenesis
and tumor progression. By contrast, in case Pten needed to be
completely lost for phenotypic consequences to be manifest,
only a complete Pten inactivation would hasten the neoplastic
process.
The discovery that phosphatidylinositol 3,4,5-trisphosphate
(PIP3) is the main in vivo substrate of PTEN (Maehama and
Dixon 1998) placed this phosphatase into a well-defined
pathway (reviewed in Vivanco and Sawyers 2002). PIP3 levels
are very low in quiescent cells, but rapidly increase upon
stimulation by growth factors, through phosphoinositide 3-
kinase (PI3K) activation. The role of PTEN is to keep the
levels of PIP3 low by dephosphorylation at the D3 position.
Loss of PTEN function results in increased PIP3 levels and
subsequent Akt hyperactivation/phosphorylation (Stambolic
et al. 1998; Di Cristofano et al. 1999; Backman et al. 2002;
Vivanco and Sawyers 2002). It may therefore be proposed
that a progressive reduction in the Pten dose could simply
result in a concomitant progressive dose-dependent increase
in Akt activation and its downstream molecular biological
consequences. Alternatively, Pten expression levels may
constitute discrete biochemical thresholds below which
qualitative functional changes would occur, contributing to
tumor progression and invasion.
CaP is the most common non-skin malignancy among
Western adult males. It is estimated that in 2003, approx-
imately 220,900 new cases and 28,900 CaP-related deaths will
occur in the United States. Approximately 70% of CaP
patients will harbor mutation or display loss of at least one
allele of PTEN ensuing in the constitutive activation of the
PI3K/mTOR pathway (Gray et al. 1998; Whang et al. 1998; Di
Cristofano and Pandolfi 2000). As aforementioned, those
mutations are in positive correlation with tumor stage and
grade, PTEN being completely lost in approximately 40% of
metastatic CaPs (Gray et al. 1998; Whang et al. 1998). We
therefore decided to focus on the prostate as an important
model system to determine genetically whether and how the
dose of Pten dictates tumor initiation and progression.
We demonstrate in vivo, in a hypomorphic mouse mutant
series, that Pten plays a crucial dose-dependent role in CaP
tumor suppression and that Pten progressive inactivation
leads to both quantitative and qualitative molecular and
biological changes towards full-blown tumorigenesis.
Results
Generation of a Hypomorphic Pten Mutant Series
We have previously reported that Pten heterozygous
mutants are tumor prone and viable, while complete Pten
inactivation results in embryonic lethality (Di Cristofano et
al. 1998, 2001a). We therefore decided to generate and
characterize a mouse mutant in which the dose of Pten would
be reduced further below the levels observed in a Ptenþ/
mutant. To this end, we at first engineered by homologous
recombination an allele of Pten that would express a wild-type
Pten gene at reduced levels, taking advantage of the well-
known phenomenon of transcriptional interference (McDe-
vitt et al. 1997; Morita et al. 2003). We therefore targeted
within Pten intron 3 the neomycin (Neo) cassette under the
control of the strong CMV promoter (Figure 1A; see also
Figure 3A) in mouse embryonic stem (ES) cells. Transcription
of the Neo cassette in the recombined allele was expected to
interfere with the transcription of the Pten gene, in turn
resulting in lower expression levels of a wild-type Pten
protein by this allele. Correctly recombined ES clones were
obtained (see Figure 3B; see Materials and Methods) and
injected into blastocysts for germline transmission. Mutants
harboring the Ptenhy allele were obtained from recombined
ES cells and were found viable, thriving, and fertile. We next
intercrossed Ptenhy/þ mice with Ptenþ/ mice to generate a
hypomorphic series (Figure 1B).
Partial Rescue of Embryonic Lethality in Pten
Hypomorphic Mutants
The further reduction of the Pten dose could indeed result
in embryonic lethality; we therefore assessed whether com-
pound Ptenhy/ mice would be born at all. In the analyzed
cohort (n¼190), viable male and female Ptenhy/mutants were
in fact obtained. However, the frequencies among various
genotypes did not follow Mendelian ratios. Out of the 25%
Ptenhy/ mutants expected in these crosses, only 10% were
born. In particular, approximately 40% of the Ptenhy/ males
and 75% of the Ptenhy/ females were lost during gestation.
This strongly suggested that a further reduction of the Pten
dose had occurred in Ptenhy/mutants and that this reduction
still results in embryonic lethality, albeit at incomplete
penetrance (the embryonic phenotype of the Ptenhy/ will be
described elsewhere; L. C. Trotman and P. P. Pandolfi,
unpublished data). Enough viable Ptenhy/ males were ob-
tained, however, and monitored for tumorigenesis in the
prostate. As predicted, a significant reduction in Pten levels
and the consequent increase in Akt activation (phospho-Akt/
Akt ratio) were observed in organs and primary cells from
Ptenhy/mutants when compared to Ptenþ/, Ptenhy/þ, and wild-
type littermates. In particular, we analyzed mouse embryonic
fibroblasts (MEFs), peripheral blood mononuclear cells
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(PBMCs), and prostates of various genotypes (Figure 1C;
Figure 2A and 2B; data not shown). Semiquantitative RT–PCR
analysis confirmed the reduction of Pten mRNA expression in
Ptenhy/ MEFs when compared to Ptenþ/ and wild-type cells
(see Figure 1D).
Massive Prostate Hyperplasia and Invasive CaP in Ptenhy/
Mutants
The levels of Pten were indeed further reduced in the
prostates from Ptenhy/mutants when compared to wild-type,
Ptenhy/þ, and Ptenþ/mice (Figure 2A and 2B). Conversely, Akt
activation was increased in Ptenhy/ mutants (Figure 2B). On
this premise, we therefore studied prostate tumorigenesis in
Ptenhy/þ (n ¼ 26), Ptenþ/ (n ¼ 24 in this study plus n ¼ 18, as
previously reported; Di Cristofano et al. 2001a), and Ptenhy/
(n¼ 14) mutants on a comparative basis. Mice were followed
throughout their lives according to the following experimen-
tal scheme: (i) all cohorts were subjected to serial monthly (in
selected cases, biweekly) nuclear magnetic resonance imaging
(MRI) (see Materials and Methods) for detection of morpho-
logical changes in the size and shape of the prostate; (ii) mice
were sacrificed at or prior to tumor detection for post-
mortem pathological analysis or when manifest sign of
distress were observed (owing to tumor codevelopment;
Ptenhy/ mutants, as Ptenþ/ mice, in fact, developed tumors
of multiple histologic origins; data not shown). Striking
differences were observed in the prostates of these three
cohorts over time. The prostates of Ptenþ/þ and Ptenþ/ mice
were never found enlarged by MRI analysis at any age (Figure
2C; see Figure 5D). Ptenþ/ mutants developed moderate/low-
grade PINs at incomplete penetrance (35%–40% approx-
imately, after a long latency of .12 mo) that were only
detected by serial postmortem analysis, as previously
reported (Figure 2F; Di Cristofano et al. 2001a). Strikingly,
however, MRI analysis immediately revealed a profound
difference in the Ptenhy/ cohort. The prostates of these mice
were found markedly enlarged, and prostate growths were
detected starting at 3 mo (see Figure 5D). By 6–8 mo, these
growths typically surpassed the size of seminal vesicles (Figure
2C and 2D). Interestingly, prostate enlargements were not
accompanied by an overall increase in total body weight or
size in Ptenhy/ mutants (data not shown). Postmortem
pathological analysis of such mutants confirmed the marked
epithelial hyperplasia of the prostate (Figure 2F). All lobes
were found to be hypercellular, with prominent macroscopic
enlargements of anterior and dorsolateral lobes. Microscopi-
cally, the regular and round prostatic glands observed in wild-
type mice were replaced by large, irregular, and complex
glands that contained multiple intraluminal papillary pro-
jections already at age 2–3 mo. Furthermore, many cells had
sizeable nuclei, clumped chromatin, and prominent nucleoli,
forming foci of epithelial dysplasia. The phenotype observed
in the Ptenhy/ mice was characterized by a wide spectrum of
levels of cellular differentiation, which was not typically
observed in the Ptenþ/ mice. As we previously reported in
Ptenþ/ and Ptenþ//p27Kip1/ mutants (Di Cristofano et al.
2001a), Pten protein expression was also still retained in the
hyperplastic prostates from Ptenhy/ mutants, and Southern
blot analysis confirmed retention of the hypomorphic Pten
allele (Figure 2E; data not shown). Importantly, approxi-
mately 25% of the Ptenhy/ mice analyzed at more than 6 mo
of age showed histological signs of local invasion, with tumor
cells disrupting the basement membrane of the gland and
growing into the surrounding stroma (Figure 2F; see Figure
5E). Thus, strikingly, a further reduction in the Pten dose as
observed in Ptenhy/ mutants when compared with Ptenþ/
mutants does lead to massive prostate hyperplasia at
complete penetrance and accelerates tumor progression
from high-grade PIN (grade 3–4 tumor as per the CaP
grading system for genetically engineered mice; Park et al.
2001) to locally invasive CaP in this mouse model.
Figure 1. Production and Analysis of a Pten
Hypomorphic Mouse Series
(A) Schematic representation of the
wild-type (þ), hypomorphic (hy), and null
() alleles of Pten. (For a detailed view,
see Figure 3A.)
(B) Breeding scheme used to produce a
Pten hypomorphic mouse series and
predicted hierarchy of Pten expression
levels.
(C) WB analysis of MEF lysates from ten
littermate primary cell cultures obtained
from a single cross (indicated in [B])
confirms predicted Pten expression hier-
archy in the hypomorphic series and
inversely related Akt phosphorylation
status (top), both verified by densitomet-
ric analysis and plotting of the Pten/actin
and phospho-Akt/Akt ratios (bottom).
(D) MEF cDNA was amplified by semi-
quantitative PCR with exon 3 (forward)
and exon 4–5 spanning (reverse) primers
for Pten. Consistent with the concept of
transcriptional interference at the Pten
locus, Pten mRNA levels in Ptenhy/ MEFs
are clearly below the level observed in
heterozygosity. Lower panels show the
quantification of Pten relative to Hprt
amplification.
DOI: 10.1371/journal.pbio.0000059.g001
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Figure 2. Ptenhy/ Mice Display Massive Hyperplasia and Invasive CaP
(A) IHC on preneoplastic anterior prostate (AP) tissue of 2-mo-old littermate mice shows decreasing Pten protein levels in the hypomorphic
series.
(B) WB analysis of the prostate lobes from (A) is shown on the left and their quantification is shown on the right.
(C) MRI of Ptenhy/mice aged 6–8 mo shows pathologic structures (encircled by dashed lines) adjacent to seminal vesicles (SV) coinciding with
displacement of the bladder (Bl), features typically associated with massive prostate tumors (right). These features were never found in Ptenþ/þ or
Ptenþ/ mice (left).
(D) Macroscopic view of the Ptenhy/ mouse from (C) confirms massive enlargement of the AP lobes, but normal-sized seminal vesicles.
(E) Quantification of WB analysis on AP lobe total lysates from the Ptenhy/ animal shown in (C) compared to preneoplastic AP of same genotype
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Generation of Conditional Prostate-Specific Pten Mutants
We next determined whether complete Pten inactivation in
the prostate would further affect CaP tumor progression. To
this end, we generated mouse mutants in which Pten exons 4
and 5 are flanked by loxP sites (Figure 3A; see Materials and
Methods). The Neo cassette was excised from the locus in vivo
by intercrossing Ptenhy/þ with EIIA-Cre transgenic mice (Lakso
et al. 1996). In these mice, the Cre recombinase is expressed
transiently, early in embryogenesis, allowing the production
of a mosaic progeny that harbors in the germline Pten alleles
in three different configurations: targeted unmodified (still
retaining the Neo cassette), Pten floxed, or Pten deleted
(Figure 3A). Breeding of these mosaic mutants allowed us to
generate mice heterozygous for the Pten floxed allele (PtenloxP
mutants; see Figure 3B).
As expected, PtenloxP mice were born following Mendelian
frequencies, viable and fertile, and were utilized for the
conditional inactivation of the Pten gene in the prostate. To
this end, we made use of two different Cre transgenic lines,
PB-Cre and PB-Cre4, in which the Cre gene is under the control
of two distinct versions of the rat Probasin (PB) gene promoter
(Maddison et al. 2000; Wu et al. 2001). The PB gene is
expressed in the prostatic epithelium postpuberty since the
gene is androgen responsive (Matusik et al. 1986). Hence,
using both PB-Cre transgenic lines, excision of the Pten gene
would occur in the prostatic epithelium postpuberty. This is
of relevance because it avoids any possible developmental
effect due to complete inactivation of Pten during prostate
organogenesis. The main difference in the two lines essen-
tially resides in the strength of the promoter. In the PB-Cre4
line (Wu et al. 2001), the Cre gene is driven by a composite
promoter, ARR2 PB, which is a derivative of the rat PB
promoter from which the PB-Cre line (Maddison et al. 2000)
was originally generated. PB-Cre4 mice express Cre at high
levels and at high penetrance, while PB-Cre mice express Cre
at lower levels and in fewer cells. This could in turn result in a
more focal or more diffuse inactivation on Pten in the
prostatic epithelium, as we could indeed document (Figure
4A). Also of note, PB-Cre and PB-Cre4 mice were crossed with
PtenloxP mutants in order to generate PB-Cre/PtenloxP/loxP
(hereafter referred to as Ptenpc1 mutants) or PB-Cre4/PtenloxP/loxP
(hereafter referred to as Ptenpc2 mutants) (see Figure 3C).
The Dose of Pten Dictates Tumor Progression in the
Prostate
We next studied the impact of complete Pten inactivation
on prostate tumorigenesis in Ptenpc1 and Ptenpc2 mutants.
Mice were followed over time exactly as described for the Pten
hypomorphic series by serial MRI and pathological analysis
over a period of approximately 18 mo (Figure 5D and 5E).
Strikingly, we observed a dramatic difference in Ptenpc1/2
mutants when compared to Ptenhy/ mutants, but also,
importantly, when comparing Ptenpc1 with Ptenpc2 mutants.
MRI and macroscopic postmortem analysis of the prostate
revealed a rapid massive enlargement of all the prostatic
lobes already manifested from 2–3 mo of age in Ptenpc2
mutants at complete penetrance (see Figure 4B; Figure 5D).
In Ptenpc1 mutants, the enlargement was less pronounced at
early stages and undetectable by MRI, but still apparent (see
Figure 4B; Figure 5D). As aforementioned, the pattern of Pten
inactivation in the prostatic epithelium was different in
Figure 3. Conditional Knockout of the Pten Gene in Mouse Prostate
(A) Map of wild-type Pten locus (top), targeting construct (second
from top), predicted targeted locus (third from top), Pten locus after
Cre-mediated excision of the Neo resistance cassette by crossing with
an EIIA-Cre mouse (fourth from top), and Pten locus after Cre-
mediated excision of the floxed exons 4 and 5 by crossing with a PB-
Cre or PB-Cre4 transgenic mouse (bottom). The genomic sequence is
depicted as a black line, with black boxes representing exons 4 and 5.
Pink and yellow boxes represent the Neo resistance and the HSV
thymidine kinase cassette (TK) and light blue triangles represent the
loxP site, respectively. The Pten genomic fragments used as a probe for
Southern blot analysis are shown (39 probe and probe 6.1). Solid
arrows represent expected fragments following hybridization with
the 39 probe upon digestion with EcoRI, and dashed arrows represent
expected fragments following hybridization with the probe 6.1 upon
digestion with XbaI. Locations of PCR primers to detect wild-type,
floxed allele (PtenloxP), and deleted allele are shown. XbaI (X), KpnI (K),
BamHI (B), and EcoRI (E) sites are shown.
(B) Genotyping of mice. Lanes 1 and 2 show Southern blot analysis of
ES cell clones with 39 probe of control (lanes 2) and recombined
clones and #176 (lane 1) after digestion with EcoRI, showing a 6 kb
wild-type band (WT) and a 2.5 kb targeted band (R). Lanes 3 and 4
(control) represent Southern blot analysis of mouse tail DNA of
offspring by crossing F1 mouse generated from #176 with an EIIA-Cre
mouse with probe 6.1 after digestion with XbaI, showing wild-type,
targeted (PtenloxP-neo), and floxed (PtenloxP) locus bands. Lanes 5, 6
(control), and 7 represent Southern blot analysis of mouse tail DNA
of offspring by crossing the mouse of lane 3 with a wild-type mouse
with probe 6.1 after digestion with XbaI. Lanes 8–14 show PCR
analysis of tail DNA of offspring by crossing a PB-Cre4 (þ), PtenloxP/þ
male with a PtenloxP/þ female with primers 1 and 2. Lanes 8, 9, and 14
indicate PtenloxP/þ , lanes 10 and 13 indicate Ptenþ/þ,and lanes 11 and
12 indicate PtenloxP/loxP. Lanes 15–17 show PCR analysis of tail DNA of
offspring by crossing a Ptenloxp/þ male with a PB-Cre4(þ), PtenloxP/þ
female with primers 1, 2, and 3. Lane 15 indicates PtenloxP/þ, lane 16
indicates Ptenþ/þ, and lane 17 indicates that the deleted allele exists in
tail DNA of this offspring.
(C) Representation of crossing scheme used to generate prostate-
specific Pten conditional mutants. PtenloxP/loxP mutants were crossed
with PB-Cre transgenic mice or PB-Cre4 transgenic mice.
DOI: 10.1371/journal.pbio.0000059.g003
from (A) and (B), labeled 8 mo and 2 mo, respectively. Note that in the enlarged hyperplastic prostate, Pten protein expression is retained (levels
are expressed relative to the corresponding wild-type animals).
(F) Histopathology (H&E) of AP lesions at 8 mo reveals transition from low- to high-grade PIN and invasion (infiltration of stromal tissue is
indicated by arrows) in Ptenhy/, while age-matched Ptenþ/ tissue only shows hyperplastic features and Ptenþ/þ tissue is unaffected. Bars are 50 lm.
DOI: 10.1371/journal.pbio.0000059.g002
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Ptenpc1 versus Ptenpc2 mutants (see Figure 4A; Ptenpc1 focal
versus Ptenpc2 widespread). This difference also correlated
with a clear difference in both the morphology and
proliferative rates of the prostatic epithelium in these two
models (see Figure 4A; see also the following paragraph).
Thus, Ptenpc2 mutants displayed a much more severe prostate
enlargement than did Ptenpc1 mutants (see Figure 4B; Figure
5D). Ptenpc1 mice displayed focal areas of epithelial hyper-
plasia, with enlarged glands formed by relatively regular cells,
while Ptenpc2 mice presented disorganized hyperplastic glands
in all lobes with signs of cellular dysplasia, containing large,
irregular cells, forming at times cryptic glandular formations
(see Figure 4A).
Even more strikingly, however, pathological analysis of
prostates from Ptenpc1 and Ptenpc2 mice revealed in both
mutants, at complete penetrance, the development of
invasive and diffuse CaP after a variable latency (see Figure
4B; Figure 5E). Tumors were in both cases made of Pten null
cells (data not shown). Continuity of local invasive disease
with that of intraepithelial lumens was often observed. The
tumors were composed of rather large, mature epithelial
cells. Neuroendocrine features, such as cytoplasmic granu-
larity and small round cells, were not seen in the tumors
analyzed (see Figure 4B). Although the tumors were clearly
invasive in both Ptenpc1 and Ptenpc2 mutants with disruption
of the basement membrane and clear signs of organ
infiltration, once again we observed differences in the CaPs
from these two models. In many instances, in Ptenpc2 mutants
more than one prostate lobe was completely effaced by the
infiltrating neoplastic cells, suggesting a multifocal tumor
origin, while invasive tumors in Ptenpc1 mutants were often
affecting only one lobe at a time and the extent of the
Figure 4. Ptenpc2 Mice Develop Invasive
CaP
(A) Histopathology analysis of wild-type,
Ptenpc1, and Ptenpc2 mice prior to tumor
onset. H&E-stained AP (top) shows the
difference in both the morphology and
proliferative rates of the prostatic epi-
thelium in these two models. IHC stain-
ing with anti-Pten antibody (bottom) was
carried out on wild-type, Ptenpc1, and
Ptenpc2 mice. In wild-type mice, strong
cytoplasmic staining was observed in
epithelial cells (arrowheads). In Ptenpc1
mice, staining was generally weak, where-
as in Ptenpc2 mice, staining was com-
plete ly absent in the prostat ic
epithelium. Original magnification,
4003.
(B) MRI (top) shows massive prostate
tumor (surrounded by dashed line) in
Ptenpc2 mice (at 6 mo) and no detectable
difference between the prostates of
Ptenpc1 or Ptenþ/þ mice (at 12 mo; arrow-
heads). Bladder (Bl) and seminal vesicles
(SV) are indicated. Macroscopic view
(second from top) of the same animals
confirms massive enlargement of both
APs in Ptenpc2 and reveals the slightly
enlarged AP of Ptenpc1 mice (encircled).
H&E staining (bottom) of the prostate
from Ptenpc1 mice was characterized by
multiple foci of PIN lesions and by the
presence of prostatic adenocarcinoma.
These lesions contained well-differenti-
ated neoplastic cells and showed focal
areas of invasion (arrowheads). H&E
stainings of prostates from Ptenpc2 mice
showed diffuse, invasive CaP with large,
undifferentiated tumor cells growing
into stromal areas.
DOI: 10.1371/journal.pbio.0000059.g004
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Figure 5. Molecular Effects of Loss of Pten and Biological Comparison of All Generated Mouse Models
(A) Ki-67 staining of AP lobe sections illustrates increasing proliferation with decreasing Pten levels (numbers are Ki-67-positive cells per 300
cells counted in percent; bars are 50 lm).
(B) The phospho-Akt/Akt ratio is sharply increased in the prostates of 10-wk-old Ptenpc2 animals, as shown by densitometric quantification of WB
analysis.
(C) AP staining with anti-phospho-Akt antibodies reveals strong plasma membrane localization of phospho-Akt and apparent reduction of p27
protein detection, whereas phospho-mTOR and phospho-threonine-FOXO3 antibodies show increased staining in Ptenpc2 versus wild-type
mouse prostates. Bars are 50 lm.
(D) Kaplan–Meier curve showing prostate enlargement as visualized by MRI. Progressive rates of mass increase for Ptenpc2 (median age, 4 mo),
Ptenhy/ (median age, 7 mo), and Ptenpc1 (median age, 16 mo) mice are found. In contrast, no prostatic size irregularities were detected in Ptenþ/þ
or Ptenþ/ mice.
(E) Incidence of invasive CaP. Invasive CaP was defined as tumor cells disrupting the basal membrane of prostatic glands and growing into the
surrounding stroma. Full penetrance was observed in both Ptenpc1 mice as well as in Ptenpc2 mice. In contrast, Ptenhy/ mice with a follow-up of
more than 6 mo displayed only 25% incidence of invasive CaP.
DOI: 10.1371/journal.pbio.0000059.g005
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infiltration was less diffuse (see Figure 4B). In addition,
tumors in the Ptenpc1 animals were well-to-moderately
differentiated while tumors in the Ptenpc2 mice were in
general high-grade, undifferentiated lesions. In contrast,
Ptenhy/ mutants displayed a spectrum of phenotypes, from
well to undifferentiated and occasionally to locally invasive
phenotypes, as previously shown.
Thus, Pten conditional inactivation in the prostate leads to
invasive and diffuse CaP at complete penetrance.
Effects of the Pten Dose on the Biology of the Prostatic
Epithelium
We studied the molecular and biological consequences of
Pten dose variations in the prostatic epithelium of our
various mutants. We included in the analysis age-matched (8-
wk-old) Ptenþ/þ, Ptenþ/, Ptenhy/, and Ptenpc2 males. The latter
mutants were used instead of Ptenpc1 mice in view of the more
widespread pattern of Pten inactivation observed in their
prostates.
First, we determined whether reduction in the Pten dose
would affect proliferation of epithelial cells. Upon Ki-67
staining, we observed a progressive increase in the prolifer-
ative rates of prostate epithelial cells, which correlated with
the reduction in Pten expression levels (Figure 5A). For
instance, approximately 10-fold more cells were found in
active proliferation in the prostates from Ptenpc2 mutants
when compared with Ptenþ/þmice. Thus, Pten inactivation, in a
dose-dependent manner, lends to epithelial cells a dramatic
growth advantage in the prostate. By contrast, MEFs of all
genotypes from the hypomorphic series did not show
noticeable differences in their growth rates under standard
culture conditions, while showing progressive activation of
the Akt signaling pathway (data not shown; see Figure 1C).
This may reflect an intrinsic differential cell-type sensitivity
to Pten inactivation, also in agreement with the fact that Pten
hypomorphism does not result in overall increased body size
and weight.
We next assessed whether and how the progressive
reduction of the Pten dose would affect the functions of
key downstream targets such as Akt, p27Kip1, mTOR, and
FOXO3 by immunohistochemistry (IHC) and Western blot
(WB) analysis (see Materials and Methods). As aforemen-
tioned, we studied the status of Akt phosphorylation, the
major known biochemical effect of Pten loss (Vivanco and
Sawyers 2002), using an anti-phospho-Akt-specific antibody
on cells and extracts from the various Pten mutants. Staining
of prostates from various genotypes with this antibody
increased proportionally to the decrease in Pten levels as
confirmed by WB analysis (see Figures 2B, 5B, and 5C; data
not shown). In addition, IHC analysis revealed a drastically
different staining pattern in prostate cells from Ptenpc2
mutants when compared with cells from other genotypes in
that phospho-Akt was found to overtly accumulate at the
plasma membrane (Figure 5C). A similar staining pattern was
observed both in Pten null epithelium prior to tumor
occurrence and in cells from overt tumors from both Ptenpc1
and Ptenpc2 mutants (data not shown). Thus, Akt is pro-
gressively activated by a reduction in the Pten dose, which in
turn results in its recruitment to the plasma membrane.
We next studied the effects of Pten inactivation on p27Kip1,
FOXO3, and mTOR, known targets of Akt kinase activity.
Phosphorylation of p27Kip1 and FOXO3 by Akt results in
their functional inactivation through multiple mechanisms
such as nuclear export, in the case of FOXO (Brunet et al.
1999), or inhibition of nuclear import and downregulation, in
the case of p27Kip1 (Mamillapalli et al. 2001; Liang et al. 2002;
Shin et al. 2002; Viglietto et al. 2002). By contrast, Akt
activation results in mTOR phosphorylation and increased
protein translation and translation initiation (Gingras et al.
2001). We previously reported that the localization or the
expression levels of p27Kip1 were not affected in Ptenþ/ and
Ptenþ//p27Kip1/ compound mutants (Di Cristofano et al.
2001a). By contrast, a progressive downregulation in p27Kip1
staining was observed in Ptenhy/ and Ptenpc2 mutants (Figure
5C; data not shown). p27Kip1 was apparently expressed at
lower levels, and fewer cells were found to express the protein
(Figure 5C). We also studied the status of FOXO3 in the
various Pten mutants, analyzing both its localization and
Figure 6. Pten Dose Affects Prostate
Tumor Progression
Ptenþ/mice develop hyperplasia, dyspla-
sia, and low-grade PIN. Ptenhy/ mice
develop at complete penetrance high-
grade PIN at a young age (8–10 wk) and
roughly 25% present invasive CaP
around 8 mo. Ptenpc mice develop
invasive CaP at complete penetrance.
(See Discussion for a detailed descrip-
tion.) p27Kip1/ mice, on the contrary,
develop only BPH. Possibilities for hu-
man therapeutic intervention derived
from our findings: in addition to in-
activation of PI3K/AKT and mTOR
enzymatic activities (in PTEN loss of
heterozygosity condition), monitoring
and elevation of PTEN expression levels
of the remaining allele could not only
prevent formation of PIN lesions (in
PTENþ/ individuals), but could impor-
tantly also be used to counteract the
progression to invasive phenotypes (as
observed in Ptenhy/mouse mutants).
DOI: 10.1371/journal.pbio.0000059.g006
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threonine phosphorylation with a specific anti-phospho-
FOXO3 antibody (see Materials and Methods). While no
noticeable differences were observed in Ptenþ/ and Ptenhy/
mutants (data not shown), increase in the levels of anti-
phospho-FOXO3 cytoplasmic staining were observed in
prostate epithelial cells from Ptenpc2 mutants when compared
to wild-type mice (Figure 5C). Complete Pten inactivation also
resulted in an increase in mTOR phosphorylation in the
prostatic epithelium of Ptenpc2 mutants (Figure 5C).
Thus, the progressive reduction of the Pten dose (and the
extent of Pten inactivation in Ptenpc1/2 mutants) affects the
proliferative rate of the prostatic epithelium and results in
molecular changes, which in turn dictates the natural history
of these lesions and tumor progression (Figure 5D and 5E).
Discussion
Our analysis allows a detailed deconstruction the molecular
genetics underlying cancer progression in the prostate and
the assessment of the key relevance of Pten and subtle
variations in its dose in controlling this process. Based on our
findings, we can now attribute distinct preneoplastic or
malignant pathological entities to distinct molecular states.
Furthermore, this new knowledge allows the reclassification,
on the basis of their true molecular nature, of pathological
lesions that at a superficial analysis appeared very similar
(Figure 6).
In this supposedly linear and multistep process, which
separates two extremely different anatomical and patholog-
ical entities, a normal prostatic epithelium from an invasive
CaP, there are, in between, a discrete number of anatomically
distinct intermediary steps, such as prostate hyperplasia .
displasia/low-grade PIN . high-grade PIN . locally invasive
CaP . diffused CaP. These entities have been recognized
before on the basis of their pathological features. The fact
that we are now able to correlate these anatomical stages with
specific molecular events, such as the level of expression of a
single tumor suppressor gene, not only represents an
integration of anatomical, descriptive findings with biological
data, but also offers the opportunity of therapeutic inter-
ventions.
We show in this study that inactivation of one Pten allele in
the mouse may lead to prostate epithelial hyperplasia, as
complete inactivation of p27Kip1 in the mouse leads to what
resembles human benign prostate hyperplasia (BPH). How-
ever, these two lesions are very different in nature and
outcome: the first, in fact, impacts only on epithelial elements
and over time evolves to low-grade PIN, while the second
impacts on both epithelial and stroma elements, representing
hyperplasia of the whole organ, but does not evolve toward
malignancy (Figure 6; Cordon-Cardo et al. 1998; Di Cristo-
fano et al. 2001a). This obviously does not exclude that loss of
p27Kip1 expression when accompanied by additional genetic
events (e.g., loss of PTEN) may lead to a completely different
outcome, as is also supported by our previous in vivo analysis
in the mouse (Figure 6; Di Cristofano et al. 2001a).
Moreover, our data demonstrate that a further reduction
in the Pten dose, as observed in the Ptenhy/ mutants,
accelerates tumor progression dramatically, eventually result-
ing in high-grade PIN and locally invasive carcinoma (Figure
6). This fact has very important therapeutic implications. As a
large number of CaP patients (more than 80%) display at
presentation loss of one PTEN allele, but do retain the other
normal PTEN allele, it could be proposed that high-grade PIN
or locally invasive prostate carcinomas could be prevented or
treated by pharmacologically modulating the expression of
the remaining PTEN allele or by antagonizing the down-
stream consequences of PTEN downregulation or partial
inactivation (e.g., PI3K/mTOR activation; Figure 6).
While the massive prostate hyperplasia/dysplasia observed
in the Ptenhy/ mutants is not, as expected, accompanied by
complete loss of Pten expression (see Figure 2E), the low
penetrance of the invasive CaP in these mutants strongly
suggest that additional events have to occur for this
pathological transition to occur. Nevertheless, it is important
to underscore that Ptenþ/ mice, unlike Ptenhy/ mutants, do
not develop invasive CaP, but only low-grade PIN lesions
(Figure 6). Thus, a further reduction of the Pten dose seems to
be essential for this process. Several possibilities, not mutually
exclusive, could be entertained: (i) a more severe reduction in
the Pten dose could facilitate cooperative tumorigenesis by
rendering the cells permissive and sensitive to the activation
of additional oncogenic pathways; (ii) the massive prostate
hyperplasia could facilitate the accumulation of additional
genetic hits (including complete Pten loss) by simply expand-
ing the pool of actively dividing cells; (iii) a more severe
reduction in the Pten dose could protect cells from apoptotic
programs that are normally triggered by the occurrence of
damaging genetics events.
The fact that Ptenhy/ mutants develop massive prostate
hyperplasia not accompanied by an overall increase in body
weight and size underscores the fact that different tissues and
organs are differentially sensitive to Pten dose variations, the
prostatic epithelium being one of the most sensitive. In
agreement with this notion, MEFs from Ptenhy/ mutants do
not display proliferative advantage in standard culture
condition over wild-type MEFs. In this respect, it is also
important to remember that, unlike p27Kip1/ mice, which
display hyperplasia of both stromal and parenchymal
components in the prostate (as well as an increase in body
mass; Fero et al. 1996; Kiyokawa et al. 1996; Nakayama et al.
1996), in Ptenhy/ mutants it is specifically the prostatic
epithelium that actively proliferates, leading to prostate
hyperplasia (Figure 6). Interestingly, this does not parallel
what is observed in other model systems, such as Drosophila,
where dose variations in the expression of Pten or down-
stream signaling components (e.g., TOR) do result in
variations in body size and mass (reviewed in Oldham and
Hafen 2003).
While we and others had previously implicated Pten
heterozygous loss in prostate tumorigenesis when in cooper-
ation with additional oncogenic events (such as loss of p27Kip1
or Nkx3.1 or the expression of the large T oncogene; Di
Cristofano et al. 2001a; Kwabi-Addo et al. 2001; Kim et al.
2002; Abate-Shen et al. 2003), we demonstrate in this article
that complete inactivation of Pten alone in the prostate has
already catastrophic consequences leading to invasive, dif-
fuse, and highly aggressive malignancies (Figure 6). Although
it cannot be formally excluded that complete Pten loss would
still cooperate with additional oncogenic events toward full-
blown transformation, this finding underscores once more
the exquisite sensitivity of the prostatic epithelium to loss of
Pten. This information should be factored in when tailoring
the treatment of CaP or high-grade PIN lesions that have
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completely lost PTEN function. These lesions may be
extremely sensitive to PI3K or mTOR inhibitors, while
modulation of PTEN expression would not be a therapeutic
option in these cases (Figure 6). On the basis of these findings,
it would seem therefore of paramount importance to
routinely assess the status of the PTEN gene and its
expression in human CaPs and precancerous lesions as a
key biomarker to opt for the most appropriate therapeutic or
chemopreventive intervention modalities. It remains to be
seen whether complete Pten inactivation in the mouse
prostate also influences the metastatic potential of these
invasive CaPs alone or in combination with additional
oncogenic events. In this respect, while MRI and postmortem
analyses have indeed revealed the presence of lung neoplastic
lesions in our conditional Pten mutants, morphological and
molecular analyses have so far excluded the metastatic nature
of these tumors (M. Niki et al., unpublished data).
The stepwise reduction in the Pten dose results in clear
progressively quantitative changes in the prostate epithelial cells
prior to tumor development. Increased cellular proliferation
correlates with increased phosphorylation of Akt. In Pten null
epithelial cells, both in the preneoplastic stage or in overt
CaPs, phospho-Akt is found to accumulate almost exclusively
at the plasma membrane (see Figure 5C). Whether this
represents the extreme consequence of Akt superactivation
or rather reflects a genuine qualitative change in Akt biology
and function in Pten null prostate epithelial cells remains to
be determined. It also remains to be resolved whether the
reduction in p27Kip1 expression is also associated with its
cytoplasmic relocalization, as previously reported in human
breast cancer cells suffering AKT hyperactivation (Liang et al.
2002; Shin et al. 2002; Viglietto et al. 2002). Taken together,
this analysis supports a Pten dose-dependent model with
progressive changes at the molecular level, arguing against a
Pten threshold model for tumor suppression.
By contrast, clear qualitative morphological changes were
observed in the prostate epithelium when analyzing the Pten
hypomorphic series. While Ptenþ/mice never display massive
prostatic enlargement, further reduction to Ptenhy/ levels
leads to a sharp increase in prostate mass. In addition, Ptenþ/
mice never develop invasive CaP, whereas Ptenhy/ mice do
(Figure 6). These data clearly support a threshold model for
Pten tumor suppression at the physiopathological level.
Similarly, qualitative morphological changes are also
caused by the number of cells suffering complete Pten
inactivation, as observed when comparing Ptenpc1 versus
Ptenpc2 mice. In Ptenpc2 mice, signs of cellular dysplasia and
irregular glandular formations were frequently observed, but
they were mostly absent from Ptenpc1 mutants. Along the same
tenet, profound mass increase was always observed at early
timepoints in Ptenpc2 mice, but not in Ptenpc1 mutants. This is
likely due to the marked difference in the number of Pten null
cells present in the parenchyma of these two models at
puberty, reflecting the different levels of Cre expression in the
two models. These observations are also consistent with a
threshold model for Pten tumor suppression as a function of
the number of Pten null cells in a given organ.
From a biological standpoint, it will be challenging to
determine in the future whether this ‘‘field effect’’ would also
play a role in the natural history of human CaP. On the one
hand, it could be speculated that human CaP likely arises
from a single transformed cell and that therefore that the
field effects observed in mouse models will not be critical
determinants in the natural history of the human disease. On
the other hand, the multistep nature of the neoplastic process
(and hence the genetic heterogeneity of the lesion) and the
fact that the tumor will eventually grow to form ‘‘fields’’ of
neoplastic cells may suggest that these effects, as well as
stromal and parenchymal interactions, are key aspects of the
human disease that the mouse model can recapitulate.
Taken together, our findings demonstrate the key impor-
tance of Pten in CaP tumor suppression and the dramatic
impact that subtle changes in Pten levels and extent of Pten
inactivation may have on tumor initiation and progression in
the prostate.
Materials and Methods
Mice. Generation and characterization of Ptenþ/ mice have been
described perviously (Di Cristofano et al. 1998, 2001a). Mice were
genotyped by PCR on tail DNA or by Southern blotting as shown.
Hypomorphic mice were generated as described in Figure 1 and
Figure 3 and tail DNA genotyped by PCR for presence of the Pten
and Ptenhy alleles (using primers 1 and 2 described below) or by
Southern blotting.
Targeting vector and generation of prostate-specific Pten-deficient
mice. A 129/Sv mouse genomic library (Stratagene, La Jolla,
California, United States) was screened with a mouse Pten probe
containing exons 4–6. To generate the targeting construct, a 4.1 Kb
KpnI–BamHI fragment containing 59 Pten genomic DNA and a 2.0 Kb
XbaI fragment containing 39 genomic DNA were cloned into pPNT.
The targeting construct was linearized with NotI and electroporated
into CJ7 ES cells. Transfectants were selected in G418 (350 lg/ml) and
gancyclovir (2 lM) and expanded for Southern blot analysis using a 39
probe. Chimeric mice were produced by microinjection of two
independently generated targeted ES cell clones with normal
karyotypes into E3.5 C57BL6/J blastocysts, then transferred to
pseudopregnant foster mothers. Chimeric males were mated with
C57BL6/J females (Jackson Laboratory, Bar Harbor, Maine, United
States), and germline transmission of the mutant allele was verified by
Southern blot analysis of tail DNA from agouti coat-colored F1
offspring. Next, PtenloxP-neo/þ mice were mated with EIIA-Cre trans-
genic mice (Lakso et al. 1996), and tail DNA from offspring was
subjected to Southern blot analysis using probe 6.1. Through these
crosses, mosaic mice harboring a Pten wild-type allele, a Pten targeted
allele (PtenloxP-neo), and a floxed allele (Ptenloxp) in their germline were
generated. These mosaic mutants were mated with wild-type mice
and tail DNA from offspring subjected to Southern blot analysis using
probe 6.1 and to PCR analysis using primer 1 (59-AAAAGTTCCCC-
TGCTGATGATTTGT-39) and primer 2 (59-TGTTTTTGACCAAT-
TAAAGTAGGCTGTG-39). PCR conditions were 35 cycles (30 sec at
958C, 1 min at 558C, and 1 min at 728C) using HotStarTaq Master Mix
(Qiagen, Valencia, California, United States), primer (0.25 lM), and
DNA (50 ng). To detect the deleted allele, primer 3 (59-CCCCCAAGT-
CAATTGTTAGGTCTGT-39) was used. PtenloxP/loxP mice were next
mated with PB-Cre transgenic mice (Maddison et al. 2000) or male PB-
Cre4 transgenic mice (Wu et al. 2001) for conditional prostate-specific
Pten inactivation.
Autopsy and histopathology. Animals were autopsied and all
tissues were examined regardless of their pathological status. Normal
and tumor tissue samples were fixed in 10% buffered formalin and
embedded in paraffin. Sections (5 lm) were stained with hematoxylin
and eosin (H&E) according to standard protocols.
Cells. Primary MEFs derived from ten littermate embryos were
produced as follows. MEFs were obtained by crossing Ptenhy/þ and
Ptenþ/ animals, embryos were harvested at 13.5 dpc, and individual
MEFs were produced and cultured as previously described (Di
Cristofano et al. 2001b) and genotyped as described above. At
passage 2, cells were harvested for WB analysis (see below) and mRNA
extraction by the TRIZOL method (GIBCO–BRL, Carlsbad, Califor-
nia, United States) and cDNA produced using the SuperScript First-
Strand Kit for RT–PCR (Invitrogen, Carlsbad, California, United
States) according to the manufacturers’ instructions. Semiquantita-
tive PCR (yielding a 102 bp amplicon) was performed with a Pten exon
3-specific forward (59-TGGATTCAAAGCATAAAAACCATTAC-39)
and an exon 4- and exon 5-specific reverse primer (59-CAAAAGGA-
TACTGTGCAACTCTGC-39) using 30 cycles of 1 min at 958C, 1 min at
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558C, and 1 min at 728C) with the PCR optimizer kit (Invitrogen) and
buffer A according to the manufacturer’s protocols. PCR amplifica-
tion of the cDNAs was performed for 25, 30, and 35 cycles, and the
amplified products were found to be in the linear range at 30 cycles.
PCR products from hypoxanthine phosphoribosyltransferase (HPRT)
control amplification with 59-CCTGCTGGATTACATTAAAG-
CACTG-39 and 59-GTCAAGGGCATATCCAACAACAAAC-39 primers
were used as standards (352 bp amplicon). For measuring prolifer-
ative rates of all MEF genotypes, cells were seeded in 12-well plates at
3,000 cells per well in medium containing 10% FBS and fixed at 2-d
intervals. Analysis and quantification were performed as previously
described (Di Cristofano et al. 2001b).
WB analysis and densitometry. Prostates from dissected animals of
all genotypes were briefly homogenized (using a Polytron homoge-
nizer; Polytron Vertrieb, Bad Wildbad, Germany), and primary MEFs
were harvested and directly lysed in 50 mM Tris (pH 7.5), 150 mM
NaCl, 1 mM EDTA, 0.1% NP-40, 1 mM sodium ortho-vanadate
(Na3VO4), 10 mM NaF, and protease inhibitor cocktail (Hoffmann–La
Roche, Basel, Switzerland) and cleared by centrifugation; concen-
trations were determined by the Bio-Rad Protein Assay (Bio-Rad
Laboratories, Hercules, California, United States); and samples were
taken into an SDS sample loading buffer. Blood was taken from the
retro-orbital cavity of anesthetized mice, red cells were lysed in lysis
buffer (0.155 M NH4Cl, 10 mM KHCO3, 1 mM EDTA), and intact cells
harvested by centrifugation. PBMCs were lysed in lysis buffer as
previously described (Di Cristofano et al. 2001b), and protein
concentrations were determined as above. Equivalents of 50 lg of
lysate per lane were used for SDS–PAGE and WB analysis. Proteins
were detected using a rabbit polyclonal anti-Pten antibody (anti-
PTEN/MMAC-1 Ab-2; NeoMarkers, Lab Vision Corporation, Fre-
mont, California, United States), anti-actin monoclonal antibody
(mAb) AC-74 (Sigma, St. Louis, Missouri, United States) for normal-
ization, and the Phospho-Akt Pathway Sampler Kit antibodies against
Akt and phospho-Serine 473 of Akt (Cell Signaling Technology,
Beverly, Massachusetts, United States) following the manufacturers’
instructions. After visualization with the ECL system (Amersham
Biosciences, Little Chalfont, United Kingdom), films were scanned
and band density was quantified using MacBas v2.5 (Fuji Photo Film
Company, Tokyo, Japan) on a Macintosh computer (Apple Computer,
Sunnyvale, California, United States).
IHC. Tissues were fixed in 4% paraformaldehyde and embedded in
paraffin, and 8 lm-thick sections were prepared. Anti-p27 mouse
mAb (catalog #610242; BD Transduction Laboratories, San Diego,
California, United States) was used at 0.5 lg/ml concentration. The
IHC detection was performed with the MOM kit from Vector
Laboratories (Burlingame, California, United States). Rabbit poly-
clonal phospho-Akt (Ser 473) antibody (catalog #9270 from Cell
Signaling Technology) was used in 1:50 dilution, and rabbit
polyclonal antibody PTEN/MMAC1 Ab-2 (catalog #RB-072-PO from
NeoMarkers) was used at 1:200 dilution. The IHC detection was
performed with the ABC kit from Vector Laboratories. These
staining procedures were carried out by the automated staining
processor Discovery from Ventana Medical Systems (Tucson, Arizona,
United States).
Anti-Ki-67 antibody (Novocastra Laboratories Ltd., Newcastle-
upon-Tyne, United Kingdom), anti-Cre antibody (Novagen, Madison,
Wisconsin, United States), and polyclonal anti-phospho-mTOR anti-
body (Cell Signaling Technology) were purchased. Anti-phospho-
FOXO3 (Thr 32) was a kind gift from Anne Brunet (Harvard
University, Cambridge, Massachusetts, United States). Paraffin sec-
tions (5 lm thickness) were fixed in ice-cold acetone and incubated in
0.1% H2O2 for 15 min to inactivate internal peroxidase. Antigen
retrieval was performed in 10 mM citric acid for 15 min using
microwave. IHC staining was performed using biotinylated secondary
antibodies followed by the Vectastain ABC Elite kit (Vector
Laboratories).
MRI analysis. Mice were assessed individually by MRI for tumor
establishment. Images were obtained on a 1.5T General Electric LX
Echo Speed Signa scanner (General Electric Medical Systems,
Milwaukee, Wisconsin, United States) using homemade foil solenoid
coils (22 mm or 27 mm inner diameter). The mice were anesthetized
with isofluorane. Images were acquired using a two-dimensional spin-
echo pulse sequence. Initially, the animal was positioned in the coil in
a holder, and sagittal scout (field of view, 120 mm) images obtained
(TR ¼ 300 ms, TE ¼ 14 ms, one excitation per phase-encoding step,
256 3 128 matrix, 3.0 mm-thick slice, 1.5 mm slice separation) to
localize the region of interest. Subsequently, high-quality T2-weighted
fast spin-echo transverse images were obtained (TR¼ 3,000–5,000 ms,
TEeff ¼ 102 ms, echo train length ¼ 12, 6–12 excitations per phase-
encoding step, 1.5 mm thick slice, field of view¼ 40 mm, 0.5 mm slice
separation, in plane resolution of 1563156 lm or 1563 208 lm).
Statistical analysis. Survival was calculated using the Kaplan–Meier
method. Log rank tests were used to compare groups by using the
SPSS 10 software package (SPSS Incorporated, Chicago, Illinois,
United States).
Acknowledgments
We thank Peter Scardino and Howard Scher for advice and
discussions; Zhenbang Chen for help with genotyping and character-
ization of the Pten hypomorphic mutants; Lisette Anne Maddison for
the genotyping of the PR-Cre transgenic mice; Katia Manova and
Craig Farrell for assistance with the automated IHC procedures;
Maria Socorro Jiao for assistance with pathological analysis; and
Mihaela Lupu and Cornelia Matei for assistance with the MRI
analysis. This study was supported, in part, by National Cancer
Institute (NCI) grants (SPORE 92629 in Prostate Cancer, MMHCC
CA-84292, and RO1 CA-82328) and by the I.T. Hirschl/M. Weill–
Caulier Foundation to PPP and CC-C. Imaging analysis was supported
by NCI grant R24CA83084 and an MSKCC NCI Core Grant to JAK.
Conflicts of Interest. The authors have declared that no conflicts of
interest exist.
Author Contributions. LCT, MN, ZAD, JAK, AD, AX, TVD, CC-C,
and PPP conceived and designed the experiments. LCT, MN, ZAD,
JAK, AD, and AX performed the experiments. LCT, MN, ZAD, JAK,
AD, AX, ASBK, TVD, CC-C, and PPP analyzed the data. PR-B, NMG,
TVD, and PPP contributed reagents/materials/analysis tools. LCT,
MN, ZAD, and PPP wrote the paper. &
References
Abate-Shen C, Banach-Petrosky WA, Sun X, Economides KD, Desai N, et al.
(2003) Nkx3.1: Pten mutant mice develop invasive prostate adenocarcinoma
and lymph node metastases. Cancer Res 63: 3886–3890.
Backman S, Stambolic V, Mak T (2002) PTEN function in mammalian cell size
regulation. Curr Opin Neurobiol 12: 516–522.
Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, et al. (1999) Akt promotes cell
survival by phosphorylating and inhibiting a Forkhead transcription factor.
Cell 96: 857–868.
Cantley LC, Neel BG (1999) New insights into tumor suppression: PTEN
suppresses tumor formation by restraining the phosphoinositide 3-kinase/
AKT pathway. Proc Natl Acad Sci U S A 96: 4240–4245.
Cordon-Cardo C, Koff A, Drobnjak M, Capodieci P, Osman I, et al. (1998)
Distinct altered patterns of p27KIP1 gene expression in benign prostatic
hyperplasia and prostatic carcinoma. J Natl Cancer Inst 90: 1284–1291.
Di Cristofano A, Pandolfi PP (2000) The multiple roles of PTEN in tumor
suppression. Cell 100: 387–390.
Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP (1998) Pten is essential
for embryonic development and tumour suppression. Nat Genet 19: 348–
355.
Di Cristofano A, Kotsi P, Peng YF, Cordon-Cardo C, Elkon KB, et al. (1999)
Impaired Fas response and autoimmunity in Ptenþ/mice. Science 285: 2122–
2125.
Di Cristofano A, De Acetis M., Koff A, Cordon-Cardo C, Pandolfi PP (2001a)
Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the
mouse. Nat Genet 27: 222–224.
Di Cristofano A, Niki M, Zhao M, Karnell FG, Clarkson B, et al. (2001b) p62dok, a
negative regulator of ras and mitogen-activated protein kinase (MAPK)
activity, opposes leukemogenesis by p210bcr-abl. J Exp Med 194: 275–284.
Fero ML, Rivkin M, Tasch M, Porter P, Carow CE, et al. (1996) A syndrome of
multiorgan hyperplasia with features of gigantism, tumorigenesis, and
female sterility in p27Kip1-deficient mice. Cell 85: 733–744.
Gingras AC, Raught B, Sonenberg N (2001) Regulation of translation initiation
by FRAP/mTOR. Genes Dev 15: 807–826.
Gray IC, Stewart LM, Phillips SM, Hamilton JA, Gray NE, et al. (1998) Mutation
and expression analysis of the putative prostate tumour-suppressor gene
PTEN. Br J Cancer 78: 1296–1300.
Hemann MT, Fridman JS, Zilfou JT, Hernando E, Paddison PJ, et al. (2003) An
epi-allelic series of p53 hypomorphs created by stable RNAi produces
distinct tumor phenotypes in vivo. Nat Genet 33: 396–400.
Kim MJ, Cardiff RD, Desai N, Banach-Petrosky WA, Parsons R, et al. (2002)
Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of
prostate carcinogenesis. Proc Natl Acad Sci U S A 99: 2884–2289.
Kiyokawa H, Kineman RD, Manova-Todorova KO, Soares VC, Hoffman ES, et
al. (1996) Enhanced growth of mice lacking the cyclin-dependent kinase
inhibitor function of p27(Kip1). Cell 85: 721–732.
Knudson AG Jr(1971) Mutation and cancer: Statistical study of retinoblastoma.
Proc Natl Acad Sci U S A 68: 820–823.
PLoS Biology | http://biology.plosjournals.org Volume 1 | Issue 3 | Page 395
Pten in Prostate Cancer Suppression
Kwabi-Addo B, Giri D, Schmidt K, Podsypanina K, Parsons R, et al. (2001)
Haploinsufficiency of the Pten tumor suppressor gene promotes prostate
cancer progression. Proc Natl Acad Sci U S A. 98: 11563–11568.
Lakso M, Pichel JG, Gorman JR, Sauer B, Okamoto Y, et al. (1996) Efficient in
vivo manipulation of mouse genomic sequences at the zygote stage. Proc
Natl Acad Sci U S A 93: 5860–5865.
Liang J, Zubovitz J, Petrocelli T, Kotchetkov R, Connor MK, et al. (2002) PKB/
Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-
mediated G1 arrest. Nat Med 8: 1153–1160.
Maddison LA, Nahm H, DeMayo F, Greenberg NM (2000) Prostate specific
expression of Cre recombinase in transgenic mice. Genesis 26: 154–156.
Maehama T, Dixon JE (1998) The tumor suppressor, PTEN/MMAC1, dephos-
phorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphos-
phate. J Biol Chem 273: 13375–13378.
Mamillapalli R, Gavrilova N, Mihaylova VT, Tsvetkov LM, Wu H, et al. (2001)
PTEN regulates the ubiquitin-dependent degradation of the CDK inhibitor
p27(KIP1) through the ubiquitin E3 ligase SCF(SKP2). Curr Biol 11: 263–267.
Matusik RJ, Kreis C, McNicol P, Sweetland R, Mullin C, et al. (1986) Regulation
of prostatic genes: Role of androgens and zinc in gene expression. Biochem
Cell Biol 64: 601–607.
McDevitt MA, Shivdasani RA, Fujiwara Y, Yang H, Orkin SH (1997) A
‘‘knockdown’’ mutation created by cis-element gene targeting reveals the
dependence of erythroid cell maturation on the level of transcription factor
GATA-1. Proc Natl Acad Sci U S A 94: 6781–6785.
Morita M, Ohneda O, Yamashita T, Takahashi S, Suzuki N, et al. (2003) HLF/
HIF-2a is a key factor in retinopathy of prematurity in association with
erythropoietin. EMBO J 22: 1134–1146.
Nakayama K, Ishida N, Shirane M, Inomata A, Inoue T, et al. (1996) Mice
lacking p27Kip1 display increased body size, multiple organ hyperplasia,
retinal dysplasia, and pituitary tumors. Cell 85: 707–720.
Oldham S, Hafen E (2003) Insulin/IGF and target of rapamycin signaling: A
TOR de force in growth control. Trends Cell Biol 13: 79–85.
Park JH, Walls JE, Galvez JJ, Kim M, Abate-Shen C, et al. (2002) Prostatic
intraepithelial neoplasia in genetically engineered mice. Am J Pathol 161:
727–735.
Podsypanina K, Ellenson LH, Nemes A, Gu J, Tamura M, et al. (1999) Mutation
of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl
Acad Sci U S A 96: 1563–1568.
Shin I, Yakes FM, Rojo F, Shin NY, Bakin AV, et al. (2002) PKB/Akt mediates
cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and
modulation of its cellular localization. Nat Med 8: 1145–1152.
Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, et al. (1998)
Negative regulation of PKB/Akt-dependent cell survival by the tumor
suppressor PTEN. Cell 95: 29–39.
Suzuki A, de la Pompa JL, Stambolic V, Elia AJ, Sasaki T, et al. (1998) High
cancer susceptibility and embryonic lethality associated with mutation of
the PTEN tumor suppressor gene in mice. Curr Biol 8: 1169–1178.
Viglietto G, Motti ML, Bruni P, Melillo RM, D’Alessio A, et al. (2002)
Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase
inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer.
Nat Med 8: 1136–1144.
Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-kinase AKT pathway
in human cancer. Nat Rev Cancer 2: 489–501.
Whang YE, Wu X, Suzuki H, Reiters RE, Tran C, et al. (1998) Inactivation of the
tumor suppressor Pten/MMAC1 in advanced human prostate cancer through
loss of expression. Proc Natl Acad Sci U S A 95: 5246–5250.
Wu X, Wu J, Huang J, Powell WC, Zhang J, et al. (2001) Generation of a prostate
epithelial cell-specific Cre transgenic mouse model for tissue-specific gene
ablation. Mech Dev 101: 61–69.
PLoS Biology | http://biology.plosjournals.org Volume 1 | Issue 3 | Page 396
Pten in Prostate Cancer Suppression
